CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Sept. 29, 2020—Siemens Healthineers will collaborate with the Centers for Disease Control and Prevention and the Joint Research Centre of the European Commission on a research project to develop a novel process for standardizing SARS-CoV-2 assays.
“One barrier to antibody test adoption is we don’t currently have an established process to determine immunity,” Deepak Nath, PhD, president of laboratory diagnostics, Siemens Healthineers, said in press statement. “Different SARS-CoV-2 antibody targets produce different levels of neutralization. Our R&D team recognized that if you could define a level at which neutralization is conferred for different targets, you could create a common ground to standardize assays—not just on antibody production, but their ability to provide immunity.”